

4260

### Hollow, Degradable poly(N-Isopropylacrylamide) Derived Nanoparticles for the Delivery of Anti-Inflammatory Peptides for the Treatment and Prevention of Post-Traumatic Osteoarthritis

Marcus A Deloney<sup>1</sup>, Kyra Smart<sup>1</sup>, Blaine Christiansen<sup>1</sup>, and Alyssa Panitch<sup>1</sup>

<sup>1</sup>University of California, Davis

**OBJECTIVES/GOALS:** Knocking down the inflammatory response following joint trauma may halt the cytokine cascade and prevent the resulting cyclic degradation of articular cartilage. MK2 inhibiting (MK2i) peptides are an emerging and promising class of pharmaceutical to treat post-traumatic osteoarthritis (PTOA); however, these peptides are susceptible to proteolytic degradation in the extracellular space. Our objective is to encapsulate MK2i in thermoresponsive hollow nanoparticles (hNPs) to knockdown the inflammatory cytokine IL-6 to prevent the cyclic degradation of articular cartilage. **METHODS/STUDY POPULATION:** NP Synthesis: N-isopropyl acrylamide (NIPAm) cores was initiated by potassium persulfate (KPS) in aqueous solution with sodium dodecylsulfate (SDS) at 70°C under a nitrogen for 2 hours. Then exposed to oxygen for 45 min, followed by a nitrogen purge. NIPAm, 2-acrylamido-2-methyl-1-propanesulfonic acid (AMPS), N,N'-bis(acryloyl)cystamine (BAC), and Acrylic Acid (AAc), in fluorescent batches rhodamine b isothiocyanate (RBITC), were polymerized around the core to form the shell. NPs were purified using tangential flow filtration. The NPs were dialyzed at 4°C for 14 days to remove the core and form hNPs. **Loading & Release:** hNPs and MK2i were incubated at 1 mg/ml at 4°C for 24 h. MK2i released into 1x PBS and analyzed on HPLC. **IL-6 Expression:** Bovine chondrocytes seeded at 10,000 cell/cm<sup>2</sup> were stimulated with 20 ng/ml IL-1b daily and treated once with 100 µg/ml MK2i loaded-NP or 100 µg/ml free MK2i treatment on day 2. Analyzed on bovine IL-6 ELISA. **In Vivo Intra Articular Injections:** 75 µl of 2 mg/ml hNPsRHB or a PBS control was injected into the right knee of 4-month old Fischer 344 (Envigo) rats. Rats were imaged daily for 7 days then euthanized, legs dissected, and imaged. **RESULTS/ANTICIPATED RESULTS:** Core removal facilitated increased MK2i release from hNPs, Fig 1A, allowing up to 63% after 5 days in PBS. The hNPs generated here offer a continual sustained release of MK2i and hNPs are non-cytotoxic (data not shown) up to 12 mg/ml. MK2i loaded-NPs significantly knocked down IL-6 production after a single treatment after 2 days, Figure 1B, and continued knockdown for up to 4 days. hNPsRBITC was successfully injected into rat joint space and was retained for at least 7-days compared to pre-injection and PBS control, Fig 1 B-C. **DISCUSSION/SIGNIFICANCE OF IMPACT:** hNPs protect MK2i from ECM degradation and offer continual sustained release into chondrocytes. Core removal allows for MK2i release *in vitro* with further sustained release compared to previous non-degradable model. The single MK2i treatment lead to a significant IL-6 knockdown bovine chondrocytes for up to 4 days in hNPs. We were able to successfully inject and retain fluorescently labeled hNPs within rat knees for 7 days. Our translational therapeutic shows the promise of delivering a degradable, non-cytotoxic hNP into the joint space to knockdown the inflammatory response to halt the cyclic progression of articular cartilage degradation and progression of PTOA. **CONFLICT OF INTEREST DESCRIPTION:** The authors declare the following

competing financial interest(s): Moerae Matrix, Inc. has a worldwide exclusive license to the CPP (MK2 inhibitor peptide). A. Panitch owns greater than 5% of Moerae Matrix, Inc.

4482

### Horizontal ridge augmentation in maxilla using bone expansion vs bone splitting techniques in adult patients: a prospective cohort

Amanda Figueroa Acevedo<sup>1</sup>, José E. Pedroza<sup>1</sup>, Augusto Elias-Boneta<sup>1</sup>, Elizabeth Orsini<sup>1</sup>, Lidia M. Guerrero<sup>1</sup>, and Sona Rivas-Tumanyan<sup>1</sup>

<sup>1</sup>University of Puerto Rico, Medical Sciences Campus

**OBJECTIVES/GOALS:** The objective of the study is to compare two horizontal bone augmentation techniques (bone expansion and bone splitting) that are currently used for horizontally deficient maxillary ridges. Bone expanded in millimeters (mm), implant stability, and patient satisfaction will be compared with each technique. **METHODS/STUDY POPULATION:** This pilot (prospective cohort) study will be divided in two sites, a private practice and the Oral and Maxillofacial Surgery (OMS) Clinic at the University of Puerto Rico, School of Dental Medicine. A total of 20 patients will be selected, 10 patients in each site. In both sites, pre-operative and post-operative Cone Beam CT radiographs will be taken to measure bone width. Implant stability will be measured using an Osstell. 2 weeks post-surgery, a patient satisfaction questionnaire will be given to patients. A two-sample T test will be used to compare techniques statistically. **RESULTS/ANTICIPATED RESULTS:** We anticipate that bone expansion will be as good as (non-inferiority) bone splitting in terms of bone expanded in millimeters to desire width, and implant diameter will not be compromised. We also expect that implants placed with the bone manipulation technique will have a higher implant stability at baseline and less pain, discomfort and swelling in terms of patient satisfaction. **DISCUSSION/SIGNIFICANCE OF IMPACT:** Our contributions here are expected to illustrate clinical and radiographic bone expansion techniques that will enhance implant placement treatment for implantologists and patient's experience.

4423

### Impact of Gender on High On-Treatment Platelet Reactivity (HPR) and Major Adverse Cardiovascular Events (MACEs) in Caribbean Hispanic patients using Clopidogrel

Hector Jose Nunez Medina<sup>1</sup>, Jorge Duconge<sup>2</sup>, Luis A. Velez<sup>3</sup>, Laura I. Fernandez<sup>3</sup>, and Orlando Arce<sup>3</sup>

<sup>1</sup>University of Puerto Rico; <sup>2</sup>University of Puerto Rico Medical Sciences Campus; <sup>3</sup>Universidad Central del Caribe

**OBJECTIVES/GOALS:** The use of P2Y12 receptor inhibitors like Clopidogrel is crucial in the prevention of thrombotic events in patients with coronary artery disease, peripheral arterial disease, and cerebrovascular disease. Variation in the level of platelet inhibition is present in many patients, and it is associated with the occurrence of major adverse cardiovascular events (MACEs). The term High-on treatment platelet reactivity (HTRP) is used to describe impaired antiplatelet inhibition while on Clopidogrel. Multiple